Dr. Sarah Goldberg: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

Article

Dr. Sarah Goldberg gives her view on more widespread availability of new mutation tests, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other LC subtypes.

[powerpress]

Dr. Rosalyn Juergens: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?

Article

Dr. Rosalyn Juergens, McMaster University, reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.

[powerpress]

Dr. David Spigel: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

Article

Dr. David Spigel gives his view on more widespread availability of new mutation tests, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other lung cancer subtypes.

[powerpress]

Subscribe to smoking status